Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Accounts Payables (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Accounts Payables for 11 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables changed N/A to $100000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $100000.0, a N/A change, with the full-year FY2025 number at $100000.0, changed N/A from a year prior.
  • Accounts Payables was $100000.0 for Q4 2025 at Crescent Biopharma, up from $89000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.2 million in Q2 2025 to a low of $89000.0 in Q3 2025.
  • A 5-year average of $1.2 million and a median of $868115.0 in 2023 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 446.93% in 2025; the steepest drop was 86.15% in 2025.
  • Crescent Biopharma's Accounts Payables stood at $2.1 million in 2021, then tumbled by 53.97% to $970191.0 in 2022, then dropped by 10.52% to $868115.0 in 2023, then crashed by 32.98% to $581794.0 in 2024, then crashed by 82.81% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Accounts Payables are $100000.0 (Q4 2025), $89000.0 (Q3 2025), and $5.2 million (Q2 2025).